bevacizumab

Type: Keyphrase
Name: bevacizumab
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Inside ASCO 2014

This year marked the 50th anniversary of the first Annual Meeting of the American Society of Clinical Oncology (ASCO). Presenting a “wrap-up” of such a momentous and mammoth event is a formidable challenge. We haven’t the space to be anywhere near comprehensive. ... [Published Cancernetwork.com - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

FDA grants Genentech’s Avastin priority review for recurrent platinum-resistant ovarian cancer

Genentech, a member of the Roche Group, has announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for ... [Published PBR - News - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 2 reports

Turkey Smuggler Of Spurious Drugs Into U.S. Pleads Guilty In Court

Article # 28140723005Posted: Jul. 23, 2014 6:15 AM GMTExecutive SummaryA smuggler from Turkey entered a guilty plea in a U.S. federal court, admitting he smuggled drugs into the U.S., including a version of Roche 's Avastin (bevacizumab) cancer treat ... [Published Health News Daily - Jul 23 2014]
Entities: Turkey, Drugs, United States
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

FDA Grants Priority Review to Bevacizumab (Avastin) for Ovarian Cancer

Approval decision expected in NovemberThe FDA has accepted a supplemental biologics license application (sBLA) for bevacizumab (Avastin, Genentech) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer, and has ... [Published PT Community - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy

AbstractPurpose To compare the 3-year visual outcome after double therapy of photodynamic therapy (PDT) with intravitreal bevacizumab (IVB)and triple therapy of PDT combined with IVB and subtenon triamcinolone acetonide (STTA) injections for polypoidal ... [Published British Journal of Ophthalmology - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 2 reports

Forum Post: RE: Oxyliplatin with 5FU and folinic acid chemotherapy plus Bevacizumab (Avastin) monoclonal antibody

> Cancer experiences> Chemotherapy> Chemotherapy - Discussion Forum> Oxyliplatin with 5FU and folinic acid chemotherapy plus Bevacizumab (Avastin) monoclonal antibody ... [Published Macmillan Cancer Support - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) ... [Published Business Wire Health News - Jul 22 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 4 reports

FDA grants Roches Avastin Priority Review for certain types of cervical cancer

Roche announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recur ... [Published BioPortfolio - Jul 15 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 2 reports

Forum Post: RE: Any advice for Oxaliplatin/5FU/Folonic & Bevacizumab regime?

Dear Jac   That's tough going over one year I truly feel for you. I am about to have my 8th session of oxy , cap and bevacizumab (avastin). I have had a few headaches with the bevacizumab but nothing  else. My side effects have come from the other tw ... [Published Macmillan Cancer Support - Jul 10 2014]
First reported Jun 30 2014 - Updated Jul 01 2014 - 2 reports

Forget the endpoint

Forget whether a study met its endpoint, having more clinical data is always a positive outcome .The debate about whether patients with metastatic colorectal cancer (mCRC) should be treated with the vascular endothelial growth factor inhibitor bevacizumab ... [Published pharmaphorum - Jul 01 2014]
First reported Jun 28 2014 - Updated Jun 29 2014 - 5 reports

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC -- ScienceDaily

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "The CALGB/SWOG ... [Published DailyMe.Com - Jun 29 2014]
First reported Jun 27 2014 - Updated Jun 28 2014 - 3 reports

EU Okays Bevacizumab in Ovarian Cancer Regorafenib in GIST

Related Biotechnology, Pharmaceutical and Healthcare NewsAnother use in a ovarian cancer is recommended for approval in Europe, as is use of regorafenib for gastrointestinal stromal tumors (GIST). International ApprovalsOriginal Article: EU Okays Bevacizumab ... [Published BioPortfolio - Jun 28 2014]

Quotes

...New treatment options are needed," said Sandra Horning, chief medical officer and head of Global Product Development, in a release. "We look forward to working with the FDA to bring this potential option to women with this difficult-to-treat cancer as soon as possible."
"We cannot avoid today the issue of the cost of care. . . . If we intend to achieve social justice in cancer care, we must define value in cancer care. . . . The assessment of value is a far more complex issue than simply adding up the price of drugs. We are clearly best positioned to serve as honest brokers in this discussion."
Original Article: NEXT ARTICLE More From BioPortfolio on "Turkey Smuggler Of Spurious Drugs Into U S Pleads Guilty In Court"
The designation of Priority Review status is granted to medicines that the FDA believes have the potential to provide "significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications." 1 The sBLA for Avastin plus chemotherapy for recurrent platinum-resistant ovarian cancer is based on data from the Phase III AURELIA trial with an FDA...

More Content

All (280) | News (227) | Reports (0) | Blogs (48) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Pharmacists Play Key Role in Oncology Revenue S... [Published Pharmacy Practice News - 11 hours ago]
“It upset me enormously that children were dyin... [Published Cancer Research UK - Jul 25 2014]
Anthracyclines and Taxanes in Breast Cancer Tre... [Published General Medicine eJournal - Jul 25 2014]
Vintafolide: A Novel Targeted Epithelial Ovaria... [Published General Medicine eJournal - Jul 25 2014]
Genentech Reports FDA Priority Review for Avastin [Published Individual.com - Jul 25 2014]
Inside ASCO 2014 [Published Cancernetwork.com - Jul 25 2014]
Yttrium-90 Radioembolization Between  First- an... [Published The ASCO Post - Jul 24 2014]
Bolt-ons rather than big deals for Roche CEO [Published Pharma Times - Jul 24 2014]
Currency takes toll on Roche first-half results [Published Pharma Letter - Jul 24 2014]
FDA Grants Genentech's Avastin Priority Review ... [Published AAPS Pharmceutica - Jul 24 2014]
Federally Funded Trials Praised—and Underfunded [Published The ASCO Post - Jul 23 2014]
Phase III Trial Shows Improved Survival With TA... [Published The ASCO Post - Jul 23 2014]
FDA grants Genentech’s Avastin priority review ... [Published PBR - News - Jul 23 2014]
Turkey Smuggler Of Spurious Drugs Into U.S. Ple... [Published Health News Daily - Jul 23 2014]
Turkey Smuggler Of Spurious Drugs Into U.S. Ple... [Published BioPortfolio - Jul 23 2014]
FDA Grants Priority Review to Bevacizumab (Avas... [Published PT Community - Jul 22 2014]
Three-year visual outcome of photodynamic thera... [Published British Journal of Ophthalmology - Jul 22 2014]
FDA Grants Priority Review again to Avastin—for... [Published Oncology Times - Jul 22 2014]
FDA grants Roche's Avastin Priority Review for ... [Published FirstWord Pharma - Jul 22 2014]
Forum Post: RE: Oxyliplatin with 5FU and folini... [Published Macmillan Cancer Support - Jul 22 2014]
ROCHE BEARER SHARE : FDA grants Roche's Avastin... [Published 4 Traders - Jul 22 2014]
FDA Grants Genentech's Avastin Priority Review ... [Published RTTNews.com - Jul 22 2014]
FDA Grants Genentech’s Avastin Priority Review ... [Published Town Hall - Jul 22 2014]
FDA Grants Genentech’s Avastin Priority Review ... [Published Business Wire Health News - Jul 22 2014]
Forum Post: Oxyliplatin with 5FU and folinic ac... [Published Macmillan Cancer Support - Jul 21 2014]
New cancer drugs approvals in Canada delayed du... [Published Pharma Letter - Jul 21 2014]
Forum Post: RE: chemo waifer [Published Macmillan Cancer Support - Jul 20 2014]
Immunotherapy for Kidney Cancer [Published News from Kidney Cancer Association - Jul 19 2014]
'Doctor' Davies on call [Published Abergavenny Chronicle - Jul 18 2014]
New European Clinical Practice Guidelines for A... [Published General Medicine eJournal - Jul 17 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA grants Genentech’s Avastin priority review ... [Published PBR - News - Jul 23 2014]
Genentech, a member of the Roche Group, has announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for ...
FDA Grants Genentech’s Avastin Priority Review ... [Published Business Wire Health News - Jul 22 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) ...
Immunotherapy for Kidney Cancer [Published News from Kidney Cancer Association - Jul 19 2014]
Joseph I. Clark, MD Immunotherapy, a type of treatment designed to enhance or restore the body’s ability to fight cancerous cells by activating the immune system, has long been a mainstay of treatment for kidney cancer, and continues to attract ...
FDA accepts sBLA, grants priority review for Ge... [Published PBR - News - Jul 16 2014]
The US Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application (sBLA) and granted priority review for Avastin (bevacizumab) plus chemotherapy to treat women with persistent, recurrent or metastatic cervical ...
FDA Grants Genentech’s Avastin Priority Review ... [Published EON Consumer - Jul 15 2014]
SOUTH SAN FRANCISCO, Calif.--(EON: Enhanced Online News)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application ...
1 2 3 4 5 6 7 8 9 10

Press Releases

sort by: Date | Relevance
PledPharma AB (publ) Interim report first quart... [Published GlobeNewswire: Acquisitions News - Apr 25 2014]
Go-ahead for PledPharma to also include Avastin... [Published GlobeNewswire: Advertising News - Apr 23 2014]
Cortice Announces Enrollment of a Phase 2 Trial... [Published GlobeNewswire: Advertising News - Mar 20 2014]
MDxHealth's PredictMDx for Glioblastoma Identif... [Published GlobeNewswire: Advertising News - Mar 04 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.